Royalty Pharma plc
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Royalty Pharma (RPRX) declared a Q4 2026 dividend of $0.235 per share, payable Dec. 10, 2026, to shareholders of record by Nov. 13, 2026. The company acquires biopharmaceutical royalties and funds biopharma development, with a portfolio of 35+ commercial products and 16 development-stage candidates.
Royalty Pharma (RPRX) will release its Q3 2026 financial results on November 4, 2026, before market open, followed by a conference call and webcast. The company is a major buyer of biopharmaceutical royalties, with a portfolio including royalties on over 35 commercial products and 17 development-stage candidates. Investors can access the call details and webcast on the company's website.
Royalty Pharma's EVP Christopher Hite sold 100,000 shares worth $5.85m on September 22, 2026, under a 10b5-1 plan. He now holds 23,200 shares directly and 270,401 indirectly. Royalty Pharma's stock has risen 70% in the past year, with a market cap of $33.5bn and P/E ratio of 31.3. The company reported Q2 2026 revenue of $768m, up 14%, and raised its 2026 outlook. Analysts BofA and TD Cowen raised price targets to $63 and $68, respectively.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning RPRX (Royalty Pharma plc). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent RPRX coverage spans earnings, technology and market movers.
In the last 30 days, RPRX insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($6.3M). The most active reporter was Urist Marshall, EVP, Research & Investments, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The dividend announcement may provide modest upside as investors price in the new yield.
The announcement sets the timing for the upcoming earnings report, which may drive short‑term trading interest.
The insider sale may signal modest downside pressure on RPRX.
Royalty Pharma may benefit from upside in RVMD's drug while providing dividend yield.
Insider sale may signal reduced confidence or portfolio rebalancing, potentially pressuring the stock short-term.
AlphAI scores every news story that mentions RPRX with an AI model for sentiment and relevance, and aggregates insider trades from Royalty Pharma plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Royalty Pharma (RPRX) declared a Q4 2026 dividend of $0.235 per share, payable Dec. 10, 2026, to shareholders of record by Nov. 13, 2026. The company acquires biopharmaceutical royalties and funds biopharma development, with a portfolio of 35+ commercial products and 16 development-stage candidates.
1 min readRoyalty Pharma (RPRX) will release its Q3 2026 financial results on November 4, 2026, before market open, followed by a conference call and webcast. The company is a major buyer of biopharmaceutical royalties, with a portfolio including royalties on over 35 commercial products and 17 development-stage candidates. Investors can access the call details and webcast on the company's website.
1 min readRoyalty Pharma's EVP Christopher Hite sold 100,000 shares worth $5.85m on September 22, 2026, under a 10b5-1 plan. He now holds 23,200 shares directly and 270,401 indirectly. Royalty Pharma's stock has risen 70% in the past year, with a market cap of $33.5bn and P/E ratio of 31.3. The company reported Q2 2026 revenue of $768m, up 14%, and raised its 2026 outlook. Analysts BofA and TD Cowen raised price targets to $63 and $68, respectively.
2 min readRevolution Medicines (RVMD) received FDA breakthrough therapy designation for its pancreatic cancer drug, RASONQUE. The stock has surged 330% in a year. Royalty Pharma (RPRX) offers diversified exposure to RVMD and other drugs, with a 1.6% dividend yield. RPRX is up 60% in a year, providing a balanced risk-reward option.
3 min readHite Christopher (EVP & Chairman, Partnering) sold 100,000 indirectly-held shares of Royalty Pharma plc (RPRX) at an average of $58.53 ($58.51–$58.93, $5.85M total) across 2 trades on 2026-09-22 under a Rule 10b5-1 trading plan.
1 min readRoyalty Pharma (RPRX) reported that pelacarsen failed its Phase 3 trial, shifting financial focus to Spinraza royalties. The company provided $500M to Ionis (IONS) in 2023, with $150M allocated to pelacarsen. RPRX expects to recover its investment through Spinraza, aiming for a modest return. The failure limits pelacarsen's potential upside, and recovery depends on Spinraza's performance.
2 min readNovartis AG (NYSE:NVS) stock fell sharply after its Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 missed the primary endpoint. The company also reported that the pelacarsen Phase 3 Lp(a)HORIZON trial for cardiovascular outcomes failed. Both Ionis Pharmaceuticals (NASDAQ:IONS) and Royalty Pharma (NASDAQ:RPRX) saw stock declines due to their ties with Novartis.
2 min readNovartis (NYSE:NVS) stock fell sharply after Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 missed primary endpoint. The company also reported that the pelacarsen cardiovascular trial failed to meet its primary endpoint. Ionis Pharmaceuticals (NASDAQ:IONS) and Royalty Pharma (NASDAQ:RPRX) shares also declined due to the trial results. Novartis is evaluating the data and plans to discuss next steps with health authorities.
2 min readRoyalty Pharma (RPRX) updated on Novartis' Phase 3 trial for pelacarsen, which failed to meet its primary endpoint. Despite this, RPRX expects to recoup its $500M investment and earn a modest return. The company reiterated its 2030 Portfolio Receipts target of $4.7B+.
2 min readSeveral biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.
2 min read
